Table 4 Treatments, sampling times, and biomarkers of tumor cells in different tissue compartments from patient 12 during disease progression
Date sampled | Treatment | Tissue compartment | ER | PR | HER2 | PIK3CA mutation in CTCs or DTCs or TCs (primary tumor or distant metastasis) |
|---|---|---|---|---|---|---|
09/2002 | N/A | Primary Tumor | 1+ rare | 2+, 10% | Neg (IHC 0) | Wild type# |
8/24/2009 | Exemestane | L2 vertebra bone metastasis (spine) | Negative | Insufficient material | Insufficient material | 8/8 |
9/23/2009 | Exemestane | Lung metastasis | 3+, 95% | Negative | Neg (FISH ratio 0.56) | Mutation present†|
9/30/2009 | Tamoxifen started | Blood | - | - | - | 0/3 |
10/8/2009 | Tamoxifen | Blood | - | - | - | 0/2 |
1/21/2010 | Fulvestrant | Blood | - | - | - | 0/4 |
2/4/2010 | Fulvestrant | Blood | - | - | - | 0/13 |
3/4/2010 | Fulvestrant | Bone marrow biopsy | Negative | Negative | Negative | 24/24 |
3/11/2010 | Cyclophos-phamide started | Blood | - | - | - | 10/20 |
4/15/2010 | Cyclophos-phamide | Blood | - | - | - | 2/7 |
7/1/2010 | Cyclophos-phamide | Blood | - | - | - | 0/27 |
8/5/2010 | Capecitabine + RAD001 (everolimus) | Blood | - | - | - | 0/50 |
10/20/2010 | Capecitabine + RAD001 (everolimus) | Blood | - | - | - | 0/0 |
11/11/2010 | Capecitabine + RAD001 (everolimus) | Blood | - | - | - | 0/2 |